Cargando…
Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study
AIMS: Reduced heart rate variability (HRV) and increased heart rate (HR) are associated with cardiovascular (CV) mortality. In the Liraglutide Effect and Action in Diabetes outcome trial, it was demonstrated a lower rate of CV events in type 2 diabetes (T2D) patients treated with liraglutide compare...
Autores principales: | Nyström, Thomas, Santos‐Pardo, Irene, Fang, Xin, Cao, Yang, Hedberg, Fredric, Jendle, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458482/ https://www.ncbi.nlm.nih.gov/pubmed/31008366 http://dx.doi.org/10.1002/edm2.58 |
Ejemplares similares
-
Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
por: Nyström, Thomas, et al.
Publicado: (2017) -
Corrigendum: Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
por: Nyström, Thomas, et al.
Publicado: (2018) -
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021) -
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial
por: Scherbak, Nikolai N., et al.
Publicado: (2023) -
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
por: Scherbak, Nikolai N., et al.
Publicado: (2023)